SYSTEBRYL™ FOR THE TREATMENT OF AL (IMMUNOGLOBULIN LIGHT CHAIN) AMYLOIDOSIS

ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation and aggregation of toxic amyloid deposits found throughout the organs in patients with AL (immunoglobulin light chain), TTR (transthyretin), and AA Amyloid diseases.

AL amyloidosis impacts an estimated 10,000 to 20,000 victims every year by attacking many of the human body's normal functioning organs (primarily heart and kidney) with toxic amyloid deposits. The result of rapid amyloid deposition within heart in these patients results in congestive heart failure and death within 4-6 months of the diagnosis of the disease. There is no effective FDA approved treatment for this disease on the market today.

Systebryl™ is believed to be the first drug to prevent and reduce AL amyloid deposits in the body (heart and kidney). Systebryl™ is being developed by ProteoTech as the first drug to reduce and eliminate amyloid deposits in heart (and other organs) in AL amyloid patients. AL amyloidosis is a type of cancer due to plasma cell (bone marrow) abnormalities that leads to insoluble amyloid deposits in heart, kidney and other tissues. Massive AL amyloid deposits in heart leads to a marked thickening of the ventricles and eventual heart failure and death. The median survival time in stage III AL amyloid patients is only 4-6 months from diagnosis. The only treatment at this time is chemotherapy which is not effective in approximately 40% of AL patients.

Due to the smaller population impacted by AL Amyloidosis, ProteoTech will request Orphan Drug Status from the FDA for its therapeutic compound in development of Systebryl™. If granted, ProteoTech will enjoy market exclusivity and added patent protection for its proprietary technologies.

AL Amyloidosis attacks key organs